- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06742801
Onyx™ vloeibare embolische IDE klinische studie
PELE IDE klinische studie, perifere Onyx™ vloeibare embolische veiligheid en effectiviteit van de Onyx™ LES voor embolisatie van arteriële bloedingen in het perifere vaatstelsel
The purpose of this study is to evaluate the safety and effectiveness of Onyx™ LES in the treatment of subjects with active arterial bleeding in the peripheral vasculature outside of the heart and brain.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
This is a pivotal, prospective, multi-center, non-randomized, single arm study. This study will enroll patients with active arterial bleeding in the peripheral vasculature confirmed by radiologic and/or endoscopic imaging and deemed suitable for embolization treatment by investigator. In this study, peripheral vasculature is defined as outside of the brain and heart.
Approximately 135 subjects will be consented to achieve 119 enrolled at up to 25 sites in the US.
This study will have two visits post-index procedure including hospital discharge visit and 30-day follow-up visit. Reintervention visits will be captured through 30 days post-index procedure.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Liza Marie
- Telefoonnummer: 7072172314
- E-mail: liza.marie@medtronic.com
Studie Contact Back-up
- Naam: Janki Shah
- Telefoonnummer: 7322662503
- E-mail: janki.shah@medtronic.com
Studie Locaties
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85054
- Werving
- Mayo Clinic
-
Contact:
- Debbie Ryan
- Telefoonnummer: 480-342-1208
- E-mail: ryan.debra29@mayo.edu
-
Hoofdonderzoeker:
- Sadeer Alzubaidi, MD
-
Contact:
- Yahaira Parker
-
-
California
-
Irvine, California, Verenigde Staten, 92627
- Werving
- University of California, Irvine
-
Contact:
- Nadine Jaoudeh, MD
- E-mail: nadine@hs.uci.edu
-
Contact:
- Kimberly Padilla
- E-mail: kpadill6@hs.uci.edu
-
Los Angeles, California, Verenigde Staten, 90095
- Werving
- University of California Los Angeles
-
Contact:
- Renato Escobar
- E-mail: raescobar@mednet.ucla.edu
-
Hoofdonderzoeker:
- Jessica Stewart, MD
-
Palo Alto, California, Verenigde Staten, 94304
- Werving
- Stanford Medical Center
-
Contact:
- Andrew Picel, MD
-
Contact:
- Abigail Bond
- E-mail: abond02@stanford.edu
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045
- Werving
- UCHealth University of Colorado Hospital
-
Contact:
- Alejandra Aguilar, MPH
- E-mail: alejandra.aguilar@cuanschutz.edu
-
Hoofdonderzoeker:
- Eduardo Bent Robinson, MD
-
-
Connecticut
-
New Haven, Connecticut, Verenigde Staten, 06510
- Werving
- Yale New Haven
-
Contact:
- Patricia Fugal
- E-mail: patricia.fugal@yale.edu
-
Contact:
- Angelo Marino, MD
- E-mail: angelo.marino@yale.edu
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60637
- Werving
- University of Chicago
-
Contact:
- Tiana Jackson
- E-mail: tiana.jackson@bsd.uchicago.edu
-
Hoofdonderzoeker:
- Brian Funaki, MD
-
-
Iowa
-
Iowa City, Iowa, Verenigde Staten, 52242
- Werving
- University of Iowa Hospitals and Clinics
-
Hoofdonderzoeker:
- Michael Hummel, MD
-
Contact:
- Victoria Mendoza
- E-mail: victoria-mendoza@uiowa.edu
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02114
- Werving
- Masschusetts General Hospital
-
Contact:
- Vincent Wu, MD
- E-mail: vwu3@mgh.harvard.edu
-
Contact:
- Justin Hill
- E-mail: jhill43@mgh.harvard.edu
-
-
Nebraska
-
Omaha, Nebraska, Verenigde Staten, 68124
- Werving
- CHI Health Creighton University Medical Center-Bergan-Mercy
-
Contact:
- Janice Mitchel
- Telefoonnummer: 402-619-9402
- E-mail: jan.mitchell@commonspirit.org
-
Hoofdonderzoeker:
- Patrick Harty
-
-
New Jersey
-
Newark, New Jersey, Verenigde Staten, 07103
- Werving
- Rutgers New Jersey Medical School
-
Hoofdonderzoeker:
- Abhishek Kumar, MD
-
Contact:
- Saharsh Patel
- E-mail: ssp186@gsbs.rutgers.edu
-
-
New York
-
Albany, New York, Verenigde Staten, 12208
- Werving
- Albany Medical Center
-
Contact:
- Nancy Spencer, NP
- E-mail: spencen@amc.edu
-
Contact:
- Gary Siskin, MD
- E-mail: sisking@amc.edu
-
New York, New York, Verenigde Staten, 10029
- Werving
- The Mount Sinai
-
Contact:
- Rajesh Patel, MD
- E-mail: rajesh.patel@mountsinai.org
-
Contact:
- Aaron Greenberg
- E-mail: aaron.greenberg@mountsinai.org
-
-
North Carolina
-
Chapel Hill, North Carolina, Verenigde Staten, 27599
- Werving
- University of North Carolina at Chapel Hill
-
Hoofdonderzoeker:
- Nima Kokabi, MD
-
Contact:
- Adriana Delgado
- E-mail: adriana_delgado@med.unc.edu
-
-
Ohio
-
Cleveland, Ohio, Verenigde Staten, 44106
- Werving
- University Hospitals Cleveland Medical Center
-
Contact:
- Lauren Hahn
- E-mail: lauren.hahn@uhhospitals.org
-
Hoofdonderzoeker:
- Salim Abboud, MD
-
Columbus, Ohio, Verenigde Staten, 43210
- Werving
- The Ohio State University
-
Contact:
- Mina Makary, MD
-
Contact:
- Gage Spears
- E-mail: gage.spears@osumc.edu
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15237
- Werving
- University of Pittsburgh Medical Center
-
Hoofdonderzoeker:
- Paula Novelli, MD
-
Contact:
- Suzanne Burdin
- E-mail: burdins@upmc.edu
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37212
- Werving
- Vanderbilt University Medical Center
-
Contact:
- Celia Nunez
- Telefoonnummer: 615-322-4559
- E-mail: celia.m.nunez@vumc.org
-
Hoofdonderzoeker:
- Anthony Borgmann, MD
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75235
- Werving
- Univ Of Texas Southwestern
-
Hoofdonderzoeker:
- Sanjeeva Kalva, MD
-
Contact:
- Camille Harry
- Telefoonnummer: 214-648-8986
- E-mail: camille.harry@utsouthwestern.edu
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- The University of Texas Health Science Center at Houston
-
Contact:
- Praneeth Nadimpalli
- E-mail: praneeth.v.nadimpalli@uth.tmc.edu
-
Contact:
- Lauren McGuire, RN
- E-mail: lauren.c.mcguire@uth.tmc.edu
-
Hoofdonderzoeker:
- Rodrick Zvavanjanja, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Patient is ≥ 22 years old.
-
Active arterial bleeding in the peripheral vasculature confirmed by radiologic and/or endoscopic imaging and deemed suitable for embolization treatment by the investigator.
In this study, peripheral vasculature is defined as outside the brain and heart.
-
Patient or legally authorized representative (LAR) is able to provide written consent to participate in the study.
-
Life expectancy of >30 days, in the opinion of the investigator at the time of enrollment.
-
Target treatment area is free from prior embolization treatment.
Exclusion Criteria:
- Pregnant or breastfeeding.
- Symptoms of active infection.
- Patient is known to be participating in the study of an investigational drug, biologic, or device.
- Contrast allergy or other contraindication to angiography, CT, or catheterization, including contrast sensitivity that cannot be adequately treated prior to index procedure.
- Known allergy to components of Onyx™.
- Target vasculature unsuitable for the delivery of Onyx™ based upon physician assessment.
- More than 4 target lesions will require embolization, in the investigator's opinion after imaging-based assessment.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Treatment with Onyx LES
Device; embolization with liquid embolic |
The proposed indication for Onyx™ LES is: Onyx™ LES is indicated for the embolization of arterial hemorrhage in the peripheral vasculature.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Freedom from Arterial Hemorrhage
Tijdsspanne: Through 30 days post-index procedure
|
Freedom from arterial hemorrhage in all target location(s) after treatment with Onyx™ LES at the index procedure without re-embolization or any other intervention at the target location(s) due to persistent or recurrent hemorrhage through 30 days. Freedom from arterial hemorrhage where an arterial hemorrhage event is defined as a type 3 or greater BARC bleeding criteria as assessed by the Clinical Events Committee (CEC) through 30 days. |
Through 30 days post-index procedure
|
|
Freedom from System-related Major Adverse Events (MAE)
Tijdsspanne: Through 30 days post-index procedure
|
The primary safety endpoint is defined as freedom from system-related Major Adverse Events (MAE) through 30 days after the point of enrollment as assessed by the CEC. |
Through 30 days post-index procedure
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Procedural Success
Tijdsspanne: At the completion of the index procedure
|
successful delivery and deployment of Onyx™ to the target location without non-target embolization or Onyx™ cast migration and the successful removal of the delivery system at the completion of the index procedure. |
At the completion of the index procedure
|
|
Technical Success
Tijdsspanne: At the completion of the index procedure
|
Technical Success is defined as absence of angiographic signs of bleeding after Onyx ™ embolization at each target location based on core lab assessment. |
At the completion of the index procedure
|
|
Reintervention
Tijdsspanne: Through 30 days post-index procedure
|
Reintervention is defined as the number of additional procedures needed to treat the target location(s) embolized with Onyx™ through 30 days following the index procedure. |
Through 30 days post-index procedure
|
|
Transfusions
Tijdsspanne: Through 30 days post-index procedure
|
Transfusions defined as the number of blood transfusions required post-index procedure through 30 days will use blood transfusions starting after the removal of the delivery system. The number of blood units used for each transfusion will also be collected. |
Through 30 days post-index procedure
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Ancillary Endpoint
Tijdsspanne: Through index procedure
|
Duration of the index procedure |
Through index procedure
|
|
Ancillary Endpoint
Tijdsspanne: Through 30 days post-index procedure
|
Length of hospitalization, post-index procedure |
Through 30 days post-index procedure
|
|
Ancillary Endpoint
Tijdsspanne: Through 30 days post-index procedure
|
Tabulate adjunctive use of other types of embolic agents to treat target locations at index procedure and reinterventions |
Through 30 days post-index procedure
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Osman Ahmed, MD, University of Chicago
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- MDT21044
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .